Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Bempegaldesleukin in Cisplatin-Ineligible MIBC
NCT04209114Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Primary completion
- Jun 2023
- Modality
- Cytokines & Interferons
- Countries
- 20
01
Overview
A Phase 3 trial of bempegaldesleukin in muscle-invasive bladder cancer (MIBC), sponsored by Bristol Myers Squibb. Started Feb 2020; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04209114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209114.